Morgan Stanley
IMRX icon

Morgan Stanley’s Immuneering IMRX Stock Holding History

Morgan Stanley’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Sell
226,491
-69,576
-24% -$352K ﹤0.01% 5154
2026
Q1 		$1.56M Sell
296,067
-193,550
-40% -$992K ﹤0.01% 4907
2025
Q4 		$3.22M Buy
489,617
+194,760
+66% +$1.25M ﹤0.01% 4489
2025
Q3 		$2.06M Buy
294,857
+93,763
+47% +$487K ﹤0.01% 4760
2025
Q2 		$678K Sell
201,094
-266,132
-57% -$456K ﹤0.01% 5314
2025
Q1 		$710K Buy
467,226
+13,126
+3% +$23.8K ﹤0.01% 5169
2024
Q4 		$999K Buy
454,100
+4,789
+1% +$9.93K ﹤0.01% 5090
2024
Q3 		$1.12M Buy
449,311
+403,259
+876% +$586K ﹤0.01% 4990
2024
Q2 		$58.9K Buy
46,052
+433
+0.9% +$712 ﹤0.01% 6123
2024
Q1 		$132K Sell
45,619
-10,529
-19% -$59K ﹤0.01% 5883
2023
Q4 		$413K Buy
56,148
+34,865
+164% +$232K ﹤0.01% 5391
2023
Q3 		$163K Sell
21,283
-4,392
-17% -$40.4K ﹤0.01% 5672
2023
Q2 		$260K Sell
25,675
-1,976
-7% -$19K ﹤0.01% 5522
2023
Q1 		$268K Sell
27,651
-17,765
-39% -$101K ﹤0.01% 5572
2022
Q4 		$220K Buy
45,416
+33,667
+287% +$298K ﹤0.01% 5626
2022
Q3 		$168K Sell
11,749
-6,538
-36% -$51.9K ﹤0.01% 5809
2022
Q2 		$98K Sell
18,287
-137
-0.7% -$731 ﹤0.01% 6285
2022
Q1 		$119K Buy
18,424
+7,787
+73% +$74.8K ﹤0.01% 6215
2021
Q4 		$172K Buy
10,637
+3,929
+59% +$95.6K ﹤0.01% 6142
2021
Q3 		$178K Buy
+6,708
New +$180K ﹤0.01% 6060

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Morgan Stanley's IMRX Position: Q2 2026 in Review

Morgan Stanley reduced its Immuneering (IMRX) stake by 24% in Q2 2026, selling an estimated $352K and leaving 226,491 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #5154.

Morgan Stanley first reported a position in IMRX in Q3 2021 and has held it in 20 quarters since. The position peaked at $3.22M in Q4 2025. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Morgan Stanley held 226,491 shares of Immuneering worth $1.13M as of Q2 2026.
  • Morgan Stanley sold 69,576 Immuneering shares in Q2 2026, an estimated $352K.
  • Immuneering made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5154 holding.
  • Morgan Stanley first reported a position in Immuneering in Q3 2021 and has held it in 20 quarters since.
  • Morgan Stanley's Immuneering position peaked at $3.22M in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.